PDCD1 and neoplasm: One example is that the sustained activation of type I IFN induces the upregulation of programmed cell death ligand 1 (PD-L1) in both tumor and dendritic cells and enhances the expression of nitric oxide synthase 2 (NOS2), leading to eventual resistance to PD-1 blockade.